Read About Genetic Testing in Acute Myeloid Leukemia

Genetic testing in acute myeloid leukemia helps identify chromosome and gene changes associated with the disease. These findings can support diagnosis, classification, risk assessment, treatment planning, and monitoring. Testing may be performed using blood or bone marrow samples and can include chromosome analysis.

Acute myeloid leukemia, often called AML, is a blood and bone marrow cancer involving abnormal myeloid cells. AML is not a single uniform condition, as genetic and chromosomal changes can vary between individuals. Genetic testing is therefore an important part of understanding the biological features of the leukemia. The information obtained from these tests can help healthcare professionals classify AML, assess potential risks, and consider appropriate treatment approaches. This article provides general educational information about the role of genetic testing in acute myeloid leukemia.

Understanding the Role of Genetic Testing in Acute Myeloid Leukemia

Genetic testing examines changes within leukemia cells, including alterations in chromosomes and specific genes. Some genetic changes may be involved in how AML develops or behaves. Testing is commonly performed on samples of bone marrow or blood collected during the diagnostic process. Different laboratory methods may be used because some tests are designed to identify large chromosomal changes, while others can detect smaller changes in individual genes.

• Chromosome analysis: This testing can identify changes involving the number or structure of chromosomes in leukemia cells.
• Fluorescence in situ hybridization: Also known as FISH, this method can detect certain chromosome abnormalities using targeted laboratory techniques.
• Molecular testing: Molecular tests can identify mutations or changes in specific genes associated with AML.
• Next generation sequencing: This approach can examine multiple genes at the same time and may identify a broader range of genetic alterations.
• Risk assessment: Certain genetic findings may be considered when healthcare teams assess whether AML has features associated with different risk categories.

Genetic testing results are generally interpreted together with other clinical information. Factors such as blood counts, bone marrow findings, a person's overall health, and the characteristics of the leukemia may also be considered. A genetic change identified in leukemia cells does not necessarily mean that the change was inherited from a parent or can be passed to children.

How Genetic Results May Support AML Classification and Care

Genetic information can contribute to the classification of AML because certain chromosome or gene changes are associated with particular forms of the disease. Classification systems may use these findings along with laboratory and clinical features to provide a clearer understanding of the leukemia. Testing may also be repeated in some situations because the genetic characteristics of leukemia cells can change over time.

• Supporting diagnosis: Specific genetic or chromosomal findings can provide additional information when AML is being evaluated.
• Guiding treatment discussions: Some genetic changes may be relevant when healthcare professionals consider available treatment options.
• Assessing prognosis: Genetic findings can contribute to discussions about how AML may behave, although they are only one part of the overall assessment.
• Monitoring disease: Certain molecular markers may be useful for tracking measurable residual disease after treatment in appropriate situations.
• Identifying clinical research options: Genetic characteristics may help determine eligibility for certain clinical trials studying AML treatments.

The meaning of genetic test results can depend on the specific test, the type of change identified, and the individual's overall medical situation. Results are typically reviewed by healthcare professionals with experience in hematology, oncology, pathology, and laboratory medicine. In some circumstances, genetic counseling may also be appropriate, particularly when there is a question about whether a genetic finding could be inherited. Understanding genetic testing can help patients and families become more familiar with the information used in the evaluation and ongoing management of acute myeloid leukemia.